140 related articles for article (PubMed ID: 30112328)
1. Effect of valproic acid on survival in glioblastoma: A prospective single-arm study.
Valiyaveettil D; Malik M; Joseph DM; Ahmed SF; Kothwal SA; Vijayasaradhi M
South Asian J Cancer; 2018; 7(3):159-162. PubMed ID: 30112328
[TBL] [Abstract][Full Text] [Related]
2. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
3. Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma-Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation.
Krauze AV; Zhao Y; Li MC; Shih J; Jiang W; Tasci E; Cooley Zgela T; Sproull M; Mackey M; Shankavaram U; Tofilon P; Camphausen K
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892181
[TBL] [Abstract][Full Text] [Related]
4. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
6. Comparative Study of Adjuvant Temozolomide Six Cycles Versus Extended 12 Cycles in Newly Diagnosed Glioblastoma Multiforme.
Bhandari M; Gandhi AK; Devnani B; Kumar P; Sharma DN; Julka PK
J Clin Diagn Res; 2017 May; 11(5):XC04-XC08. PubMed ID: 28658891
[TBL] [Abstract][Full Text] [Related]
7. Late toxicity in long-term survivors from a phase 2 study of concurrent radiation therapy, temozolomide and valproic acid for newly diagnosed glioblastoma.
Krauze AV; Mackey M; Rowe L; Chang MG; Holdford DJ; Cooley T; Shih J; Tofilon PJ; Camphausen K
Neurooncol Pract; 2018 Nov; 5(4):246-250. PubMed ID: 30402263
[TBL] [Abstract][Full Text] [Related]
8. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Happold C; Gorlia T; Chinot O; Gilbert MR; Nabors LB; Wick W; Pugh SL; Hegi M; Cloughesy T; Roth P; Reardon DA; Perry JR; Mehta MP; Stupp R; Weller M
J Clin Oncol; 2016 Mar; 34(7):731-9. PubMed ID: 26786929
[TBL] [Abstract][Full Text] [Related]
9. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Kerkhof M; Dielemans JC; van Breemen MS; Zwinkels H; Walchenbach R; Taphoorn MJ; Vecht CJ
Neuro Oncol; 2013 Jul; 15(7):961-7. PubMed ID: 23680820
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Redjal N; Reinshagen C; Le A; Walcott BP; McDonnell E; Dietrich J; Nahed BV
J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors.
Mallick S; Gandhi AK; Joshi NP; Kumar A; Puri T; Sharma DN; Haresh KP; Gupta S; Julka PK; Rath GK; Sarkar C
Indian J Med Paediatr Oncol; 2015; 36(2):99-104. PubMed ID: 26157286
[TBL] [Abstract][Full Text] [Related]
12. Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Watanabe S; Kuwabara Y; Suehiro S; Yamashita D; Tanaka M; Tanaka A; Ohue S; Araki H
Eur J Clin Pharmacol; 2017 Mar; 73(3):357-363. PubMed ID: 27889835
[TBL] [Abstract][Full Text] [Related]
13. The addition of Valproic acid to concurrent radiation therapy and temozolomide improves patient outcome: a Correlative analysis of RTOG 0525, SEER and a Phase II NCI trial.
Krauze AV; Megan M; Theresa CZ; Peter M; Shih JH; Tofilon PJ; Rowe L; Gilbert M; Camphausen K
Cancer Stud Ther; 2020 Mar; 5(1):. PubMed ID: 34621499
[TBL] [Abstract][Full Text] [Related]
14. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
15. Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.
Skardelly M; Dangel E; Gohde J; Noell S; Behling F; Lepski G; Borchers C; Koch M; Schittenhelm J; Bisdas S; Naumann A; Paulsen F; Zips D; von Hehn U; Ritz R; Tatagiba MS; Tabatabai G
Oncologist; 2017 May; 22(5):570-575. PubMed ID: 28360216
[TBL] [Abstract][Full Text] [Related]
16. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244.
Elinzano H; Glantz M; Mrugala M; Kesari S; Piccioni DE; Kim L; Pan E; Yunus S; Coyle T; Timothy K; Evans D; Mantripragada K; Boxerman J; DiPetrillo T; Donahue JE; Hebda N; Mitchell KM; Rosati KL; Safran H
Am J Clin Oncol; 2018 Feb; 41(2):159-162. PubMed ID: 26658237
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial).
Mallick S; Kunhiparambath H; Gupta S; Benson R; Sharma S; Laviraj MA; Upadhyay AD; Julka PK; Sharma D; Rath GK
J Neurooncol; 2018 Oct; 140(1):75-82. PubMed ID: 29936695
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 Study of Radiation Therapy Plus Low-Dose Temozolomide Followed by Temozolomide and Irinotecan for Glioblastoma: NRG Oncology RTOG Trial 0420.
Lieberman FS; Wang M; Robins HI; Tsien CI; Curran WJ; Werner-Wasik M; Smith RP; Schultz C; Hartford AC; Zhang P; Mehta MP
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):878-886. PubMed ID: 30496882
[TBL] [Abstract][Full Text] [Related]
20. Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.
Jackson WC; Tsien CI; Junck L; Leung D; Hervey-Jumper S; Orringer D; Heth J; Wahl DR; Spratt DE; Cao Y; Lawrence TS; Kim MM
J Neurooncol; 2018 May; 138(1):155-162. PubMed ID: 29388034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
